HRP20090684T1 - Kondicionirani sastav krvi i metoda za njegovu proizvodnju - Google Patents
Kondicionirani sastav krvi i metoda za njegovu proizvodnju Download PDFInfo
- Publication number
- HRP20090684T1 HRP20090684T1 HR20090684T HRP20090684T HRP20090684T1 HR P20090684 T1 HRP20090684 T1 HR P20090684T1 HR 20090684 T HR20090684 T HR 20090684T HR P20090684 T HRP20090684 T HR P20090684T HR P20090684 T1 HRP20090684 T1 HR P20090684T1
- Authority
- HR
- Croatia
- Prior art keywords
- blood
- composition according
- muscle
- blood composition
- interleukin
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 title claims abstract 43
- 239000008280 blood Substances 0.000 title claims abstract 43
- 239000000203 mixture Substances 0.000 title claims abstract 34
- 238000000034 method Methods 0.000 title claims abstract 18
- 230000001143 conditioned effect Effects 0.000 title claims abstract 7
- 238000004519 manufacturing process Methods 0.000 title claims 3
- 241001465754 Metazoa Species 0.000 claims abstract 8
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 4
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 4
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 4
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 4
- 102000000589 Interleukin-1 Human genes 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 4
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 4
- 102000003814 Interleukin-10 Human genes 0.000 claims 4
- 108090000174 Interleukin-10 Proteins 0.000 claims 4
- 102000003816 Interleukin-13 Human genes 0.000 claims 4
- 108090000176 Interleukin-13 Proteins 0.000 claims 4
- 102000004388 Interleukin-4 Human genes 0.000 claims 4
- 108090000978 Interleukin-4 Proteins 0.000 claims 4
- 102000004889 Interleukin-6 Human genes 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 4
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 4
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims 4
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 4
- 229940076144 interleukin-10 Drugs 0.000 claims 4
- 229940028885 interleukin-4 Drugs 0.000 claims 4
- 229940100601 interleukin-6 Drugs 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims 4
- 208000029578 Muscle disease Diseases 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000011534 incubation Methods 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- -1 polyethylene Polymers 0.000 claims 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 206010061822 Drug intolerance Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010061958 Food Intolerance Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010049565 Muscle fatigue Diseases 0.000 claims 1
- 206010070521 Muscle hernia Diseases 0.000 claims 1
- 208000029549 Muscle injury Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 239000010431 corundum Substances 0.000 claims 1
- 229910052593 corundum Inorganic materials 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910044991 metal oxide Inorganic materials 0.000 claims 1
- 150000004706 metal oxides Chemical class 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 210000001087 myotubule Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 229920003023 plastic Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920000915 polyvinyl chloride Polymers 0.000 claims 1
- 239000004800 polyvinyl chloride Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000010453 quartz Substances 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000002682 anti-psoriatic effect Effects 0.000 abstract 1
- 230000000767 anti-ulcer Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006005016A DE102006005016A1 (de) | 2006-02-03 | 2006-02-03 | Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung |
| PCT/EP2007/000903 WO2007090569A1 (de) | 2006-02-03 | 2007-02-02 | Konditionierte blutzusammensetzung und verfahren zu deren herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090684T1 true HRP20090684T1 (hr) | 2010-02-28 |
Family
ID=37965046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090684T HRP20090684T1 (hr) | 2006-02-03 | 2009-12-23 | Kondicionirani sastav krvi i metoda za njegovu proizvodnju |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20090047242A1 (el) |
| EP (2) | EP2156841A1 (el) |
| JP (1) | JP2009525297A (el) |
| KR (1) | KR20080100425A (el) |
| CN (1) | CN101378768A (el) |
| AT (1) | ATE446100T1 (el) |
| AU (1) | AU2007213996A1 (el) |
| BR (1) | BRPI0707360A2 (el) |
| CA (1) | CA2640002A1 (el) |
| CY (1) | CY1109735T1 (el) |
| DE (2) | DE102006005016A1 (el) |
| DK (1) | DK1984006T3 (el) |
| EA (1) | EA014435B1 (el) |
| ES (1) | ES2335446T3 (el) |
| HK (1) | HK1125835A1 (el) |
| HR (1) | HRP20090684T1 (el) |
| MX (1) | MX2008009807A (el) |
| PL (1) | PL1984006T3 (el) |
| PT (1) | PT1984006E (el) |
| RS (1) | RS51247B (el) |
| SI (1) | SI1984006T1 (el) |
| UA (1) | UA90048C2 (el) |
| WO (1) | WO2007090569A1 (el) |
| ZA (1) | ZA200805975B (el) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
| US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
| US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
| US20080269762A1 (en) * | 2007-04-25 | 2008-10-30 | Biomet Manufacturing Corp. | Method and device for repair of cartilage defects |
| US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| WO2009108890A1 (en) | 2008-02-27 | 2009-09-03 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| DE102008028684A1 (de) * | 2008-06-17 | 2009-12-24 | Kopetzky, Robert, Dr. | Blutbeutel |
| US8460227B2 (en) | 2008-11-17 | 2013-06-11 | Arthrex, Inc. | Cytokine concentration system |
| US20120093936A1 (en) | 2009-04-07 | 2012-04-19 | Velin-Pharma A/S | Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system |
| CN102573790B (zh) | 2009-08-27 | 2017-03-22 | 拜欧米特生物制剂有限责任公司 | 用于产生白介素‑1受体拮抗剂的可植入装置 |
| US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
| WO2011029903A1 (en) | 2009-09-10 | 2011-03-17 | Flemming Velin | Method for the preparation of micro-rna and its therapeutic application |
| DE202009017772U1 (de) | 2009-12-10 | 2011-04-21 | Orthogen Ag | Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid |
| KR20140003398A (ko) | 2010-09-03 | 2014-01-09 | 바이오멧 바이오로직스, 엘엘씨 | 인터루킨-1 수용체 길항제를 전달하는 방법 및 조성물 |
| DE102010042356A1 (de) * | 2010-10-12 | 2012-04-12 | Henke-Sass, Wolf Gmbh | Behälter für die Herstellung einer konditionierten Blutzusammensetzung |
| US9011846B2 (en) | 2011-05-02 | 2015-04-21 | Biomet Biologics, Llc | Thrombin isolated from blood and blood fractions |
| US9205110B2 (en) | 2012-07-18 | 2015-12-08 | Arthrex, Inc. | Enhanced autologous growth factor production and delivery system |
| DE102012019088A1 (de) | 2012-09-28 | 2014-04-03 | Orthogen Ag | Antibakterielle Arzneimittelpräparate |
| DK2956150T3 (da) | 2013-02-12 | 2021-11-01 | Lacerta Tech Inc | Serumfraktion af trombocyt-rig fibrin |
| US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| EP2829278A1 (de) * | 2013-07-23 | 2015-01-28 | Scientific BioTech GmbH | Serum zur Behnandlung von Krankheiten |
| EP3074507B1 (en) | 2013-11-26 | 2022-01-05 | Biomet Biologics, LLC | Methods of mediating macrophage phenotypes |
| AU2014361728A1 (en) * | 2013-12-09 | 2016-06-02 | Cytokine Medical Australia Pty Ltd | Apparatus for producing therapeutically active proteins in blood and uses thereof |
| US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
| US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
| EP3352769A1 (en) * | 2016-08-17 | 2018-08-01 | Orthogen AG | Anti-ageing pharmaceutical preparation |
| EP3613424A1 (en) | 2018-08-23 | 2020-02-26 | Orthogen AG | Novel methods for the production of pharmaceutical agents |
| DE102021124752A1 (de) * | 2021-09-24 | 2023-03-30 | Ad Lentus GmbH | Autologes Therapeutikum und Verfahren zur Herstellung desselben |
| CN114146096B (zh) * | 2021-11-25 | 2024-04-02 | 成都清科生物科技有限公司 | 一种富含细胞因子的条件血清的制备方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4244437A1 (de) * | 1992-12-29 | 1994-07-28 | Horst Dr Med Kief | Verfahren zur Gewinnung körpereigener Zytokine |
| DE19903876B4 (de) * | 1999-02-01 | 2006-09-28 | Orthogen Gentechnologie Gmbh | Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten |
| US20020081324A1 (en) * | 2002-01-22 | 2002-06-27 | Twine Rebecca Wright | Method of treating aging skin and wrinkles using a combination of growth factors that is commercially prepared or derived from one's own blood |
-
2006
- 2006-02-03 DE DE102006005016A patent/DE102006005016A1/de not_active Withdrawn
-
2007
- 2007-02-02 DK DK07711428.8T patent/DK1984006T3/da active
- 2007-02-02 KR KR1020087018622A patent/KR20080100425A/ko not_active Application Discontinuation
- 2007-02-02 CN CNA2007800044614A patent/CN101378768A/zh active Pending
- 2007-02-02 BR BRPI0707360-7A patent/BRPI0707360A2/pt not_active IP Right Cessation
- 2007-02-02 ES ES07711428T patent/ES2335446T3/es active Active
- 2007-02-02 EP EP09013177A patent/EP2156841A1/de not_active Withdrawn
- 2007-02-02 RS RSP-2010/0012A patent/RS51247B/sr unknown
- 2007-02-02 WO PCT/EP2007/000903 patent/WO2007090569A1/de active Application Filing
- 2007-02-02 JP JP2008552751A patent/JP2009525297A/ja not_active Withdrawn
- 2007-02-02 MX MX2008009807A patent/MX2008009807A/es not_active Application Discontinuation
- 2007-02-02 US US12/162,022 patent/US20090047242A1/en not_active Abandoned
- 2007-02-02 EA EA200870222A patent/EA014435B1/ru not_active IP Right Cessation
- 2007-02-02 AU AU2007213996A patent/AU2007213996A1/en not_active Abandoned
- 2007-02-02 SI SI200730130T patent/SI1984006T1/sl unknown
- 2007-02-02 UA UAA200810851A patent/UA90048C2/ru unknown
- 2007-02-02 CA CA002640002A patent/CA2640002A1/en not_active Abandoned
- 2007-02-02 ZA ZA200805975A patent/ZA200805975B/xx unknown
- 2007-02-02 AT AT07711428T patent/ATE446100T1/de active
- 2007-02-02 DE DE502007001793T patent/DE502007001793D1/de active Active
- 2007-02-02 PT PT07711428T patent/PT1984006E/pt unknown
- 2007-02-02 EP EP07711428A patent/EP1984006B1/de not_active Revoked
- 2007-02-02 PL PL07711428T patent/PL1984006T3/pl unknown
-
2009
- 2009-04-28 HK HK09103942.4A patent/HK1125835A1/xx not_active IP Right Cessation
- 2009-12-23 HR HR20090684T patent/HRP20090684T1/hr unknown
-
2010
- 2010-01-15 CY CY20101100046T patent/CY1109735T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200870222A1 (ru) | 2008-12-30 |
| DE502007001793D1 (de) | 2009-12-03 |
| RS51247B (sr) | 2010-12-31 |
| PL1984006T3 (pl) | 2010-03-31 |
| EP1984006A1 (de) | 2008-10-29 |
| UA90048C2 (ru) | 2010-03-25 |
| BRPI0707360A2 (pt) | 2011-05-03 |
| KR20080100425A (ko) | 2008-11-18 |
| EP1984006B1 (de) | 2009-10-21 |
| ES2335446T3 (es) | 2010-03-26 |
| WO2007090569A1 (de) | 2007-08-16 |
| CN101378768A (zh) | 2009-03-04 |
| MX2008009807A (es) | 2008-09-26 |
| ATE446100T1 (de) | 2009-11-15 |
| EA014435B1 (ru) | 2010-12-30 |
| PT1984006E (pt) | 2010-01-20 |
| JP2009525297A (ja) | 2009-07-09 |
| DK1984006T3 (da) | 2010-03-01 |
| WO2007090569A8 (de) | 2008-02-28 |
| EP2156841A1 (de) | 2010-02-24 |
| CY1109735T1 (el) | 2014-09-10 |
| ZA200805975B (en) | 2010-08-25 |
| HK1125835A1 (en) | 2009-08-21 |
| US20090047242A1 (en) | 2009-02-19 |
| AU2007213996A1 (en) | 2007-08-16 |
| SI1984006T1 (sl) | 2010-02-26 |
| CA2640002A1 (en) | 2007-08-16 |
| DE102006005016A1 (de) | 2007-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090684T1 (hr) | Kondicionirani sastav krvi i metoda za njegovu proizvodnju | |
| JP2009525297A5 (el) | ||
| Chereddy et al. | PLGA nanoparticles loaded with host defense peptide LL37 promote wound healing | |
| DeKosky et al. | Upregulation of nerve growth factor following cortical trauma | |
| AU2014238304B2 (en) | Treatment of inflammatory respiratory disease using biological solutions | |
| Tsurushima et al. | Enhanced bone formation using hydroxyapatite ceramic coated with fibroblast growth factor-2 | |
| JP6581208B2 (ja) | 創傷治癒の方法 | |
| WO2021174738A1 (zh) | 表面pd-l1分子过表达的间充质干细胞膜包被的仿生纳米颗粒及其制备和应用 | |
| AU2014238363B2 (en) | Methods and acellular compositions for treating inflammatory disorders | |
| WO2009008928A2 (en) | Methods for treating nervous system injury and disease | |
| CN105338990A (zh) | 治疗炎症性疾病的方法和非免疫原性组合物 | |
| JP7189123B2 (ja) | 血小板ペレット溶解物の調製及び神経学的障害の処置のためのその使用 | |
| JP2023001265A (ja) | 長期間の安定性を有する脱細胞化ヒト羊水調製物 | |
| KR20100016492A (ko) | 올리고글루로네이트 및 올리고갈락투로네이트 조성물 | |
| MX2013011040A (es) | Metodo para productos terapeuticos encapsulados y usos de los mismos. | |
| CN109844101B (zh) | 使用极化巨噬细胞的细胞疗法，用于组织再生 | |
| Barussi et al. | Intratracheal therapy with autologous bone marrow-derived mononuclear cells reduces airway inflammation in horses with recurrent airway obstruction | |
| Couto et al. | The mechanisms underlying the biological response to wear debris in periprosthetic inflammation | |
| William et al. | Functional recovery of spinal cord injury following application of intralesional bone marrow mononuclear cells embedded in polymer scaffold-two year follow-up in a canine | |
| JP2008514633A (ja) | 線条体または黒質緻密部における神経学的欠損の治療 | |
| Xia et al. | Continual deletion of spinal microglia reforms astrocyte scar favoring axonal regeneration | |
| EP2687224A1 (en) | Medicament for wound treatment | |
| CA2831154C (en) | Use of pertussis toxin as a therapeutic agent | |
| Cheng et al. | The effects of intrapleural polyclonal anti-tumor necrosis factor alpha (TNFα) Fab fragments on pleurodesis in rabbits | |
| Li et al. | Preconditioning mesenchymal stromal cells with flagellin enhances the anti‑inflammatory ability of their secretome against lipopolysaccharide‑induced acute lung injury |